TLDR
- ENvue Medical (FEED) stock jumped 38.17% on Monday
- A 714-bed Detroit-area teaching hospital purchased its ENvue Navigation Platform and feeding tubes
- The deal brings ENvue’s total U.S. hospital count to 39
- The hospital is part of a Southeast Michigan health system where ENvue was already deployed
- Despite the stock move, FEED trades at $1.43 with a market cap of just $1.56 million and has fallen 96% over the past year
ENvue Medical, Inc. (FEED) stock shot up 38.17% on Monday after the company announced a new hospital purchase in the Detroit metropolitan area, expanding its U.S. footprint to 39 facilities.
A 714-bed teaching hospital and Level I Trauma Center in Southeast Michigan bought the ENvue Navigation Platform system along with feeding tubes. The facility is already part of a health system where ENvue had previously been deployed.
The hospital is a major regional anchor, with specialty institutes covering oncology, cardiovascular care, and pediatrics. It runs multiple ICUs including a dedicated Level III Neuro-ICU.
Marc Waldman, Vice President of Commercial at ENvue Medical, called the deal part of the company’s focus on strategic account expansion. “Preeminent teaching and non-teaching hospitals alike are seeking innovative technologies that can improve workflow efficiency while supporting cost containment and patient safety initiatives,” he said.
FEED was trading at $1.43 at the time of writing, giving the company a market cap of roughly $1.56 million. The stock has fallen around 96% over the past year.
What the ENvue Platform Does
The ENvue Navigation Platform is a minimally invasive electromagnetic navigation system that helps clinicians place feeding tubes into the gastrointestinal tract. It received FDA 510(k) clearance for adult use.
The system provides real-time bedside visualization of tube movement during the placement procedure. ENvue says future versions of the platform could expand into pediatric and vascular access applications.
CEO Doron Besser said the Michigan expansion “reflects continued momentum in our commercial execution.” ENvue is headquartered in Tyler, Texas, with R&D operations in Tel-Aviv and Nesher, Israel.
Financial Picture
The commercial wins come against a difficult financial backdrop. Revenue declined 18% to $2.69 million, and the company remains unprofitable. It has been burning through cash at a pace that analysts have flagged as a concern.
Despite that, the stock has landed on at least one platform’s “Most Undervalued” list, with a Fair Value estimate suggesting potential upside from current levels.
ENvue also has some recent business momentum beyond hospital sales. The U.S. Patent and Trademark Office issued a Notice of Allowance for a patent on a feeding tube design that combines electromagnetic navigation with a distal-tip camera. The patent covers 18 claims.
The company also signed a distribution agreement with U-Deliver to expand its ENFit syringes into non-acute care channels, targeting home and long-term care settings.
Marc Waldman, who was recently appointed as VP of Commercial, is tasked with driving U.S. commercialization strategy beyond the current hospital base.
ENvue also amended its Long Term Incentive Plan to align with Israeli tax laws, incorporating restricted stock units under Section 102. The amendment also reflects the company’s recent name change from NanoVibronix, Inc. to ENvue Medical, Inc.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
